Most Read Articles
Audrey Abella, 20 Dec 2019
The combination of the immunomodulatory agent lenalidomide and the monoclonal antibody rituximab (R2) proved effective and safe in individuals ≥70 years with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL) compared with rituximab alone, according to a post hoc analysis of the phase III AUGMENT* trial presented at ASH 2019. 
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
23 Dec 2019
The use of dienogest at 1 mg per day to treat primary dysmenorrhoea is well tolerated and attenuates symptoms of pain, as shown in the results of a phase II trial.

Product Highlight - Vaxigrip Tetra

27 Sep 2019
• A quadrivalent vaccine proven to be immunogenic to help protect patients against 4 key influenza strains1-4
Simple dosing and convenient to use - 1 compact box with unique dosage of 0.5 mL [syringe with attached needle]4
• Indicated for 6 months and above 4


References:
1. VaxigripTetra® vaccine. Public Assessment Report, November 2016. Available at http://mri.cts-mrp.eu/Human/Downloads/DE_H_1949_001_PAR.pdf Accessed October 2018.
2. Gresset-Bourgeois V, et al. Expert Rev Vaccines 2018;17[1]:1-11.
3. Sesay S, et al. Human Vaccin lmmunother 2018;14[3]:596-608, DOl:10.1080/21645515.2017.1384106.
4. Sanofi Pasteur. VaxigripTetra® Product Prescribing Information.


Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 20 Dec 2019
The combination of the immunomodulatory agent lenalidomide and the monoclonal antibody rituximab (R2) proved effective and safe in individuals ≥70 years with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL) compared with rituximab alone, according to a post hoc analysis of the phase III AUGMENT* trial presented at ASH 2019. 
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
23 Dec 2019
The use of dienogest at 1 mg per day to treat primary dysmenorrhoea is well tolerated and attenuates symptoms of pain, as shown in the results of a phase II trial.